In the past week, HOTH stock has gone up by 5.30%, with a monthly gain of 63.53% and a quarterly surge of 33.65%. The volatility ratio for the week is 6.63%, and the volatility levels for the last 30 days are 13.63% for Hoth Therapeutics Inc The simple moving average for the past 20 days is 24.65% for HOTH’s stock, with a 40.62% simple moving average for the past 200 days.
Is It Worth Investing in Hoth Therapeutics Inc (NASDAQ: HOTH) Right Now?
The stock has a 36-month beta value of 0.55. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HOTH is 13.14M, and at present, short sellers hold a 0.43% of that float. On June 18, 2025, the average trading volume of HOTH was 1.12M shares.
HOTH) stock’s latest price update
The stock price of Hoth Therapeutics Inc (NASDAQ: HOTH) has jumped by 6.92 compared to previous close of 1.30. Despite this, the company has seen a gain of 5.30% in its stock price over the last five trading days. prnewswire.com reported 2025-06-18 that HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck HOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing. Study Results: Liver weight increased from 1.11g → 1.32g across 0 → 3.0 mg/kg No adverse effects on kidney, spleen, or thymus 100% clean safety profile — no visible lesions or gross pathology Validates safety of HT-KIT in vivo Robb Knie, CEO: “These results strengthen our confidence in HT-KIT as we advance toward clinical trials.
Analysts’ Opinion of HOTH
Many brokerage firms have already submitted their reports for HOTH stocks, with The Benchmark Company repeating the rating for HOTH by listing it as a “Speculative Buy.” The predicted price for HOTH in the upcoming period, according to The Benchmark Company is $10 based on the research report published on October 15, 2019 of the previous year 2019.
HOTH Trading at 45.36% from the 50-Day Moving Average
After a stumble in the market that brought HOTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOTH starting from Knie Robb, who purchase 25,000 shares at the price of $0.67 back on Aug 16 ’24. After this action, Knie Robb now owns 58,131 shares of Hoth Therapeutics Inc, valued at $16,750 using the latest closing price.
Stock Fundamentals for HOTH
The total capital return value is set at -0.84. Equity return is now at value -99.35, with -92.33 for asset returns.
Based on Hoth Therapeutics Inc (HOTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -278.64.
Currently, EBITDA for the company is -8.19 million with net debt to EBITDA at 1.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.08.
Conclusion
To sum up, Hoth Therapeutics Inc (HOTH) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
